These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 37197442)

  • 41. First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.
    Mori K; Pradere B; Moschini M; Mostafaei H; Laukhtina E; Schuettfort VM; Sari Motlagh R; Soria F; Teoh JYC; Egawa S; Powles T; Shariat SF;
    Eur J Cancer; 2021 Jul; 151():35-48. PubMed ID: 33962359
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and safety of immune checkpoint inhibitors for hepatocellular carcinoma patients with macrovascular invasion or extrahepatic spread: a systematic review and meta-analysis of 54 studies with 6187 hepatocellular carcinoma patients.
    Han CL; Tian BW; Yan LJ; Ding ZN; Liu H; Mao XC; Tian JC; Xue JS; Tan SY; Dong ZR; Yan YC; Hong JG; Chen ZQ; Wang DX; Li T
    Cancer Immunol Immunother; 2023 Jul; 72(7):1957-1969. PubMed ID: 36811662
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognostic efficacy and prognostic factors of TACE plus TKI with ICIs for the treatment of unresectable hepatocellular carcinoma: A retrospective study.
    Han Z; Yang F; Zhang Y; Wang J; Ni Q; Zhu H; Zhou X; Gao H; Lu J
    Front Oncol; 2022; 12():1029951. PubMed ID: 36591442
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A systematic review and meta-analysis evaluating the impact of antibiotic use on the clinical outcomes of cancer patients treated with immune checkpoint inhibitors.
    Crespin A; Le Bescop C; de Gunzburg J; Vitry F; Zalcman G; Cervesi J; Bandinelli PA
    Front Oncol; 2023; 13():1075593. PubMed ID: 36937417
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative analysis of antibiotic exposure association with clinical outcomes of chemotherapy versus immunotherapy across three tumour types.
    Kulkarni AA; Ebadi M; Zhang S; Meybodi MA; Ali AM; DeFor T; Shanley R; Weisdorf D; Ryan C; Vasu S; Rashidi A; Patel MR
    ESMO Open; 2020 Sep; 5(5):e000803. PubMed ID: 32900789
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Predicting survival of NSCLC patients treated with immune checkpoint inhibitors: Impact and timing of immune-related adverse events and prior tyrosine kinase inhibitor therapy.
    Sayer MR; Mambetsariev I; Lu KH; Wong CW; Duche A; Beuttler R; Fricke J; Pharoan R; Arvanitis L; Eftekhari Z; Amini A; Koczywas M; Massarelli E; Roosan MR; Salgia R
    Front Oncol; 2023; 13():1064169. PubMed ID: 36860308
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The impact of antibiotics on efficacy of immune checkpoint inhibitors in malignancies: A study based on 44 cohorts.
    Wu Q; Liu J; Wu S; Xie X
    Int Immunopharmacol; 2021 Mar; 92():107303. PubMed ID: 33465728
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effect of anti-PD-1/PD-L1 antibodies combined with VEGF receptor tyrosine kinase inhibitors versus bevacizumab in unresectable hepatocellular carcinoma.
    Zeng H; Xu Q; Wang J; Xu X; Luo J; Zhang L; Luo C; Ying J; Li J
    Front Immunol; 2023; 14():1073133. PubMed ID: 36756114
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immune checkpoint inhibitor (ICI)-based treatment beyond progression with prior immunotherapy in patients with stage IV non-small cell lung cancer: a retrospective study.
    Tian T; Yu M; Yu Y; Wang K; Tian P; Luo Z; Ding Z; Wang Y; Gong Y; Zhu J; Zou B; Sio TT; Alves A; Liu Y; Huang M; Lu Y
    Transl Lung Cancer Res; 2022 Jun; 11(6):1027-1037. PubMed ID: 35832458
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Uptake and Survival Outcomes Following Immune Checkpoint Inhibitor Therapy Among Trial-Ineligible Patients With Advanced Solid Cancers.
    Parikh RB; Min EJ; Wileyto EP; Riaz F; Gross CP; Cohen RB; Hubbard RA; Long Q; Mamtani R
    JAMA Oncol; 2021 Dec; 7(12):1843-1850. PubMed ID: 34734979
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and safety of hepatic arterial infusion chemotherapy combined with immune checkpoint inhibitors and tyrosine kinase inhibitors in advanced hepatocellular carcinoma: A systematic review and meta‑analysis.
    Li Z; Xu Y; Qu W; Liu P; Zhu Y; Li H; Guo Y; Liu X
    Oncol Lett; 2023 Dec; 26(6):534. PubMed ID: 38020293
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer.
    Graf RP; Fisher V; Weberpals J; Gjoerup O; Tierno MB; Huang RSP; Sayegh N; Lin DI; Raskina K; Schrock AB; Severson E; Haberberger JF; Ross JS; Creeden J; Levy MA; Alexander BM; Oxnard GR; Agarwal N
    JAMA Netw Open; 2022 Mar; 5(3):e225394. PubMed ID: 35357449
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? A meta-analysis.
    Lopes S; Pabst L; Dory A; Klotz M; Gourieux B; Michel B; Mascaux C
    Front Immunol; 2023; 14():1070076. PubMed ID: 36776847
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antibiotic Therapy is Associated with Worse Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib.
    Pomej K; Balcar L; Scheiner B; Semmler G; Meischl T; Mandorfer M; Reiberger T; Müller C; Trauner M; Pinter M
    J Hepatocell Carcinoma; 2021; 8():1485-1493. PubMed ID: 34877268
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and safety of combined targeted therapy and immunotherapy versus targeted monotherapy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
    Yang TK; Yu YF; Tsai CL; Li HJ; Yang PS; Huang KW; Cheng JC
    BMC Cancer; 2022 Oct; 22(1):1085. PubMed ID: 36271374
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma.
    Scheiner B; Roessler D; Phen S; Lim M; Pomej K; Pressiani T; Cammarota A; Fründt TW; von Felden J; Schulze K; Himmelsbach V; Finkelmeier F; Deibel A; Siebenhüner AR; Shmanko K; Radu P; Schwacha-Eipper B; Ebert MP; Teufel A; Djanani A; Hucke F; Balcar L; Philipp AB; Hsiehchen D; Venerito M; Sinner F; Trauner M; D'Alessio A; Fulgenzi CAM; Pinato DJ; Peck-Radosavljevic M; Dufour JF; Weinmann A; Kremer AE; Singal AG; De Toni EN; Rimassa L; Pinter M
    JHEP Rep; 2023 Jan; 5(1):100620. PubMed ID: 36578451
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy.
    Cortellini A; Ricciuti B; Facchinetti F; Alessi JVM; Venkatraman D; Dall'Olio FG; Cravero P; Vaz VR; Ottaviani D; Majem M; Piedra A; Sullivan I; Lee KA; Lamberti G; Hussain N; Clark J; Bolina A; Barba A; Benitez JC; Gorría T; Mezquita L; Hoton D; Aboubakar Nana F; Besse B; Awad MM; Pinato DJ
    Ann Oncol; 2021 Nov; 32(11):1391-1399. PubMed ID: 34400292
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors.
    Wu YL; van Hyfte G; Özbek U; Reincke M; Gampa A; Mohamed YI; Nishida N; Wietharn B; Amara S; Lee PC; Scheiner B; Balcar L; Pinter M; Vogel A; Weinmann A; Saeed A; Pillai A; Rimassa L; Naqash AR; Muzaffar M; Huang YH; Kaseb AO; Kudo M; Pinato DJ; Ang C
    Front Oncol; 2023; 13():1128569. PubMed ID: 36865801
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Use of Antibiotics during Immune Checkpoint Inhibitor Treatment Is Associated with Lower Survival in Hepatocellular Carcinoma.
    Cheung KS; Lam LK; Seto WK; Leung WK
    Liver Cancer; 2021 Nov; 10(6):606-614. PubMed ID: 34950183
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An Up-To-Date Investigation Into the Correlation Between Proton Pump Inhibitor Use and the Clinical Efficacy of Immune Checkpoint Inhibitors in Advanced Solid Cancers: A Systematic Review and Meta-Analysis.
    Liu C; Guo H; Mao H; Tong J; Yang M; Yan X
    Front Oncol; 2022; 12():753234. PubMed ID: 35280736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.